NCT06314867View on ClinicalTrials.gov

Clinical Study on Lot-to-lot Consistency and Immune Persistence of Three Commercial Batches of PPSV23

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

990

Participants

Timeline

Start Date

January 30, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

June 30, 2028

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

23 Valent Pneumococcal Polysaccharide Vaccine (lot 1)

All subjects were vaccinated with 1 dose of 23 Valent Pneumococcal Polysaccharide Vaccine (batch number: Y202112011), intramuscularly injected into the lateral deltoid muscle of the upper arm.

BIOLOGICAL

23 Valent Pneumococcal Polysaccharide Vaccine (lot 2)

All subjects were vaccinated with 1 dose of 23 Valent Pneumococcal Polysaccharide Vaccine (batch number: Y202112012), intramuscularly injected into the lateral deltoid muscle of the upper arm.

BIOLOGICAL

23 Valent Pneumococcal Polysaccharide Vaccine (lot 3)

All subjects were vaccinated with 1 dose of 23 Valent Pneumococcal Polysaccharide Vaccine (batch number: Y202112013), intramuscularly injected into the lateral deltoid muscle of the upper arm.

Trial Locations (1)

610041

Sichuan Center for Disease Control and Prevention, Chengdu

All Listed Sponsors
lead

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

INDUSTRY